These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 35369022)

  • 1. Patiromer and Spironolactone in Resistant Hypertension and Advanced CKD: Analysis of the Randomized AMBER Trial.
    Agarwal R; Rossignol P; Budden J; Mayo MR; Arthur S; Williams B; White WB
    Kidney360; 2021 Mar; 2(3):425-434. PubMed ID: 35369022
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patiromer to Enable Spironolactone Use in the Treatment of Patients with Resistant Hypertension and Chronic Kidney Disease: Rationale and Design of the AMBER Study.
    Agarwal R; Rossignol P; Garza D; Mayo MR; Warren S; Arthur S; Romero A; White WB; Williams B
    Am J Nephrol; 2018; 48(3):172-180. PubMed ID: 30176673
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial.
    Agarwal R; Rossignol P; Romero A; Garza D; Mayo MR; Warren S; Ma J; White WB; Williams B
    Lancet; 2019 Oct; 394(10208):1540-1550. PubMed ID: 31533906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): results in the pre-specified subgroup with heart failure.
    Rossignol P; Williams B; Mayo MR; Warren S; Arthur S; Ackourey G; White WB; Agarwal R
    Eur J Heart Fail; 2020 Aug; 22(8):1462-1471. PubMed ID: 32452085
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patiromer to Enable Spironolactone in Patients with Resistant Hypertension and CKD (AMBER): Results in the Prespecified Subgroup with Diabetes.
    Agarwal R; Rossignol P; Mayo MR; Conrad A; Arthur S; Williams B; White WB
    Clin J Am Soc Nephrol; 2021 Sep; 16(9):1407-1409. PubMed ID: 34162695
    [No Abstract]   [Full Text] [Related]  

  • 6. A comparative post hoc analysis of finerenone and spironolactone in resistant hypertension in moderate-to-advanced chronic kidney disease.
    Agarwal R; Pitt B; Palmer BF; Kovesdy CP; Burgess E; Filippatos G; Małyszko J; Ruilope LM; Rossignol P; Rossing P; Pecoits-Filho R; Anker SD; Joseph A; Lawatscheck R; Wilson D; Gebel M; Bakris GL
    Clin Kidney J; 2023 Feb; 16(2):293-302. PubMed ID: 36864892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evolution of Patiromer Use: a Review.
    Ali W; Bakris G
    Curr Cardiol Rep; 2020 Jul; 22(9):94. PubMed ID: 32648072
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of an individualized dose titration regimen of patiromer to prevent hyperkalaemia in patients with heart failure and chronic kidney disease.
    Pitt B; Bushinsky DA; Kitzman DW; Ruschitzka F; Metra M; Filippatos G; Rossignol P; Du Mond C; Garza D; Berman L; Lainscak M;
    ESC Heart Fail; 2018 Jun; 5(3):257-266. PubMed ID: 29369537
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Resistant Hypertension in Chronic Kidney Disease (CKD): Prevalence, Treatment Particularities, and Research Agenda.
    Georgianos PI; Agarwal R
    Curr Hypertens Rep; 2020 Sep; 22(10):84. PubMed ID: 32880742
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and Efficacy of Patiromer in Hyperkalemic Patients with CKD: A Pooled Analysis of Three Randomized Trials.
    Haller H; Bianchi S; McCafferty K; Arthur S; Quinn CM; Budden J; Weir MR
    Kidney360; 2022 Dec; 3(12):2019-2026. PubMed ID: 36591361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mineralocorticoid Receptor Antagonists for Hypertension Management in Advanced Chronic Kidney Disease: BLOCK-CKD Trial.
    Bakris G; Yang YF; Pitt B
    Hypertension; 2020 Jul; 76(1):144-149. PubMed ID: 32520623
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Can patiromer allow for intensified renin-angiotensin-aldosterone system blockade with losartan and spironolactone leading to decreased albuminuria in patients with chronic kidney disease, albuminuria and hyperkalaemia? An open-label randomised controlled trial: MorphCKD.
    Mårup FH; Peters CD; Christensen JH; Birn H
    BMJ Open; 2022 Feb; 12(2):e057503. PubMed ID: 35190442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spironolactone and Resistant Hypertension in Heart Failure With Preserved Ejection Fraction.
    Rossignol P; Claggett BL; Liu J; Vardeny O; Pitt B; Zannad F; Solomon S
    Am J Hypertens; 2018 Mar; 31(4):407-414. PubMed ID: 29228101
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of hypertension in advanced kidney disease.
    Georgianos PI; Agarwal R
    Curr Opin Nephrol Hypertens; 2022 Jul; 31(4):374-379. PubMed ID: 35727171
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potassium binders for chronic hyperkalaemia in people with chronic kidney disease.
    Natale P; Palmer SC; Ruospo M; Saglimbene VM; Strippoli GF
    Cochrane Database Syst Rev; 2020 Jun; 6(6):CD013165. PubMed ID: 32588430
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors.
    Weir MR; Bakris GL; Bushinsky DA; Mayo MR; Garza D; Stasiv Y; Wittes J; Christ-Schmidt H; Berman L; Pitt B;
    N Engl J Med; 2015 Jan; 372(3):211-21. PubMed ID: 25415805
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patiromer: a clinical review.
    Montaperto AG; Gandhi MA; Gashlin LZ; Symoniak MR
    Curr Med Res Opin; 2016; 32(1):155-64. PubMed ID: 26456884
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of patiromer in the treatment of hyperkalemia in chronic kidney disease patients with hypertension on diuretics.
    Weir MR; Mayo MR; Garza D; Arthur SA; Berman L; Bushinsky D; Wilson DJ; Epstein M
    J Hypertens; 2017 May; 35 Suppl 1(Suppl 1):S57-S63. PubMed ID: 28129247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure).
    Eschalier R; McMurray JJ; Swedberg K; van Veldhuisen DJ; Krum H; Pocock SJ; Shi H; Vincent J; Rossignol P; Zannad F; Pitt B;
    J Am Coll Cardiol; 2013 Oct; 62(17):1585-93. PubMed ID: 23810881
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors of hyperkalemia risk following hypertension control with aldosterone blockade.
    Khosla N; Kalaitzidis R; Bakris GL
    Am J Nephrol; 2009; 30(5):418-24. PubMed ID: 19738369
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.